Edgewise [EWTX] vs Liquidia [LQDA] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Edgewise wins in 8 metrics, Liquidia wins in 7 metrics, with 0 ties. Edgewise appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricEdgewiseLiquidiaBetter
P/E Ratio (TTM)-37.26-13.51Edgewise
Price-to-Book Ratio2.80126.72Edgewise
Debt-to-Equity Ratio0.741,319.26Edgewise
PEG Ratio-39.35-0.42Edgewise
EV/EBITDA-6.14-14.31Liquidia
Profit Margin (TTM)0.00%58.00%Liquidia
Operating Margin (TTM)0.00%-424.41%Edgewise
Return on Equity-27.41%-389.13%Edgewise
Return on Assets (TTM)-19.06%-39.74%Edgewise
Free Cash Flow (TTM)$-110.34M$-101.87MLiquidia
1-Year Return-51.91%106.13%Liquidia
Price-to-Sales Ratio (TTM)N/A99.94N/A
Enterprise Value$1.06B$1.96BLiquidia
EV/Revenue RatioN/A101.34N/A
Gross Profit Margin (TTM)N/A83.06%N/A
Revenue per Share (TTM)$0$0Liquidia
Earnings per Share (Diluted)$-1.56$-1.82Edgewise
Beta (Stock Volatility)0.290.16Liquidia
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Edgewise vs Liquidia Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Edgewise-1.92%-2.54%3.16%21.73%29.75%-43.21%
Liquidia1.92%0.26%-18.30%83.61%83.91%88.93%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Edgewise-51.91%47.31%-48.83%-48.83%-48.83%-48.83%
Liquidia106.13%328.89%699.30%108.01%108.01%108.01%

News Based Sentiment: Edgewise vs Liquidia

Edgewise

News based Sentiment: POSITIVE

The month was marked by positive developments for Edgewise Therapeutics, including the upcoming presentation of long-term clinical data, increased institutional investment, and strategic employee inducement awards. While some stock price volatility occurred, the overall narrative suggests growing confidence in the company's potential.

View Edgewise News Sentiment Analysis

Liquidia

News based Sentiment: MIXED

Liquidia is facing both opportunities and challenges this month. The potential expansion into the IPF market is a positive catalyst, but the ongoing patent litigation with United Therapeutics and bearish options trading activity introduce significant uncertainty. This creates a mixed investment narrative.

View Liquidia News Sentiment Analysis

Performance & Financial Health Analysis: Edgewise vs Liquidia

MetricEWTXLQDA
Market Information
Market Cap i$1.65B$1.93B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,035,6603,320,420
90 Day Avg. Volume i982,2172,676,227
Last Close$15.35$22.86
52 Week Range$10.60 - $38.12$9.71 - $29.94
% from 52W High-59.73%-23.65%
All-Time High$40.49 (Mar 29, 2021)$38.46 (Oct 08, 2018)
% from All-Time High-62.09%-40.56%
Growth Metrics
Quarterly Revenue GrowthN/A1.42%
Quarterly Earnings GrowthN/A1.42%
Financial Health
Profit Margin (TTM) i0.00%0.58%
Operating Margin (TTM) i0.00%-4.24%
Return on Equity (TTM) i-0.27%-3.89%
Debt to Equity (MRQ) i0.741,319.26
Cash & Liquidity
Book Value per Share (MRQ)$5.59$0.18
Cash per Share (MRQ)$5.64$2.01
Operating Cash Flow (TTM) i$-124,779,000$-116,055,000
Levered Free Cash Flow (TTM) i$-74,084,128$-71,345,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Edgewise vs Liquidia

MetricEWTXLQDA
Price Ratios
P/E Ratio (TTM) i-37.26-13.51
Forward P/E i-8.46-14.38
PEG Ratio i-39.35-0.42
Price to Sales (TTM) iN/A99.94
Price to Book (MRQ) i2.80126.72
Market Capitalization
Market Capitalization i$1.65B$1.93B
Enterprise Value i$1.06B$1.96B
Enterprise Value Metrics
Enterprise to Revenue iN/A101.34
Enterprise to EBITDA i-6.14-14.31
Risk & Other Metrics
Beta i0.290.16
Book Value per Share (MRQ) i$5.59$0.18

Financial Statements Comparison: Edgewise vs Liquidia

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)EWTXLQDA
Revenue/Sales i$0$3.12M
Cost of Goods Sold iN/A$1.52M
Gross Profit iN/A$1.60M
Research & Development i$33.56M$6.97M
Operating Income (EBIT) i$-42.61M$-35.43M
EBITDA i$-42.04M$-33.25M
Pre-Tax Income i$-36.12M$-38.37M
Income Tax iN/AN/A
Net Income (Profit) i$-36.12M$-38.37M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)EWTXLQDA
Cash & Equivalents i$49.92M$169.76M
Total Current Assets i$443.18M$177.21M
Total Current Liabilities i$21.12M$60.52M
Long-Term Debt i$3.56M$109.66M
Total Shareholders Equity i$429.72M$49.71M
Retained Earnings i$-419.37M$-595.76M
Property, Plant & Equipment i$5.26M$11.49M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)EWTXLQDA
Operating Cash Flow i$-28.51M$-26.68M
Capital Expenditures i$-44,000$-330,000
Free Cash Flow i$-37.91M$-31.01M
Debt Repayment iN/A$-2.19M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricEWTXLQDA
Shares Short i8.57M18.47M
Short Ratio i10.707.92
Short % of Float i0.10%0.27%
Average Daily Volume (10 Day) i1,035,6603,320,420
Average Daily Volume (90 Day) i982,2172,676,227
Shares Outstanding i94.84M84.68M
Float Shares i60.53M60.86M
% Held by Insiders i0.00%0.13%
% Held by Institutions i1.14%0.71%

Dividend Analysis & Yield Comparison: Edgewise vs Liquidia

MetricEWTXLQDA
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A